Shield Therapeutics plc Stock

Equities

STX

GB00BYV81293

Biotechnology & Medical Research

Market Closed - London S.E. 11:35:25 2024-05-16 am EDT 5-day change 1st Jan Change
1.85 GBX 0.00% Intraday chart for Shield Therapeutics plc +25.42% -72.39%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
Sales 2024 * 24.13M 30.55M Sales 2025 * 71.12M 90.02M Capitalization 14.47M 18.31M
Net income 2024 * -18M -22.78M Net income 2025 * 11M 13.92M EV / Sales 2024 * 1.55 x
Net Debt 2024 * 22.98M 29.09M Net Debt 2025 * 20.91M 26.47M EV / Sales 2025 * 0.5 x
P/E ratio 2024 *
-0.86 x
P/E ratio 2025 *
3.34 x
Employees 27
Yield 2024 *
-
Yield 2025 *
-
Free-Float 48.78%
More Fundamentals * Assessed data
Dynamic Chart
1 week+25.42%
Current month+37.04%
1 month+21.31%
3 months-68.38%
6 months-69.42%
Current year-72.39%
More quotes
1 week
1.55
Extreme 1.55
2.10
1 month
1.06
Extreme 1.0625
2.10
Current year
1.06
Extreme 1.0625
7.80
1 year
1.06
Extreme 1.0625
12.85
3 years
1.06
Extreme 1.0625
62.60
5 years
1.06
Extreme 1.0625
202.00
10 years
1.06
Extreme 1.0625
202.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 57 21-05-31
Director of Finance/CFO 47 Jan. 15
Chief Operating Officer - 11-07-31
Members of the board TitleAgeSince
Chairman 68 18-07-25
Director/Board Member 66 16-01-31
Director/Board Member 57 21-05-09
More insiders
Date Price Change Volume
24-05-16 1.85 0.00% 448,345
24-05-15 1.85 -7.50% 2,025,571
24-05-14 2 +5.26% 3,812,812
24-05-13 1.9 +24.59% 13,915,190
24-05-10 1.525 +3.39% 4,566,400

Delayed Quote London S.E., May 16, 2024 at 11:35 am EDT

More quotes
Shield Therapeutics plc is a United Kingdom-based commercial-stage pharmaceutical company. The Company is focused on the commercialization of its oral iron therapy for iron deficiency. The Company's lead product, Feraccru/Accrufer (ferric maltol), is a stable, non-salt-based oral therapy for adults with iron deficiency with or without anemia. Ferric maltol is approved in the United States, European Union, United Kingdom and Switzerland for the treatment of iron deficiency with or without anemia in adults. The Company's subsidiaries include Shield Therapeutics (DE) GmbH, Shield TX (Switzerland) AG, Shield TX (UK) Limited and Shield Therapeutics Inc.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
0.0185 GBP
Average target price
0.16 GBP
Spread / Average Target
+764.86%
Consensus

Quarterly revenue - Rate of surprise

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW